Shree Ganesh Remedies Limited (SGRL) Fair Value & Analysis
Healthcare · IN · Market cap ₹8.7B
Fair value as of: Jul 6, 2026
From 24 valuation models · updated today
Share price +3.3% over the past month.
Price vs Fair Value (12 months)
12‑month range ₹400.40 – ₹709.55 · fair‑value band ₹117.83 – ₹346.12 · the ₹673.90 price screens above the ₹222.01 fair value. As of Jul 6, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Shree Ganesh Remedies Limited (SGRL) currently trades at ₹673.90, while our model-based Fair Value estimate is ₹222.01 — implying the stock looks roughly 67.1% overvalued today. We read business quality at 59/100 (solid quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).
Over the trailing twelve months, Shree Ganesh Remedies Limited generated revenue of ₹1.1B at a net margin of 16.3%. Revenue grew 35.9% year over year. It earns a return on equity of 11.5%. Net debt stands at ₹173M. Fundamentals as of Jul 6, 2026
Our scenario range runs from ₹117.83 (bear case) to ₹346.12 (bull case); at ₹673.90, the current price sits above that range. The share trades about 11% below its 52-week high and 77% above its 52-week low, currently above its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -48% fair-value upside — at -67%, SGRL screens richer than that median.
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jul 6, 2026. TTM = trailing twelve months.
About the company
Shree Ganesh Remedies Limited engages in the manufacture and sale of pharmaceutical drug intermediates for active pharmaceutical ingredient (API) and fine chemicals in India. It provides anti-arrhythmic, anti-cancer, anti-depressant, anti-diabetic, anti-diarrheal, anti-fungal, anti-histamine, anti-inflammatory, anti-parasitic, anti-psychotic, anticholinergic, birth-control, cardiovascular, gastrointestinal, neurological disorder, ophthalmic, opioid, and veterinary API intermediates. The company also offers fine and specialty chemicals, such as agro-chemicals, electronics, flavor and fragrance, life-sciences, and polymer chemicals, as well as other specialty chemicals, including cyclopropanecarboxaldehyde, hexamethylendichloride, octamethylendiamine, and suberonitrile for pharmaceutical, agricultural, and various chemical applications. In addition, it is involved in customized chemistry development and manufacturing; assets and infrastructure; and customized process of …
Revenue & earnings trend
FY2022 – FY2026 · reported fiscal years
Shree Ganesh Remedies Limited reported revenue of ₹1.1B in FY2026 versus ₹713M in FY2022, a compound +11.3%/yr. Reported net income was ₹178M in FY2026, compounding +7.3%/yr from FY2022.
Is SGRL fairly valued? → Check now
Similar stocks
10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate (as of Jul 6, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Jiangsu Hengrui Pharmaceuticals Co 1276 | HK$57.85 | HK$29.84 | -48% |
| Sun Pharmaceutical Industries Limited SUNPHARMA | ₹1,786 | ₹991.46 | -44% |
| Zoetis Inc Z1TS34 | R$24.93 | R$6.33 | -75% |
| Hansoh Pharmaceutical Group 3692 | HK$29.30 | HK$23.90 | -18% |
| Divi's Laboratories Limited DIVISLAB | ₹6,639 | ₹1,281 | -81% |
| Torrent Pharmaceuticals Limited TORNTPHARM | ₹4,421 | ₹1,504 | -66% |
| Cipla Limited CIPLA | ₹1,416 | ₹1,466 | +4% |
| Zydus Lifesciences Limited ZYDUSLIFE | ₹1,089 | ₹841.98 | -23% |
| Dr. Reddy's Laboratories Limited DRREDDY | ₹1,278 | ₹595.34 | -53% |
| PharmaEssentia Corporation 6446 | 1,095 TWD | 365.87 TWD | -67% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Shree Ganesh Remedies Limited (SGRL) undervalued?
What is the fair value of SGRL?
What is the quality score of SGRL?
What is the revenue of Shree Ganesh Remedies Limited (SGRL)?
What is the net profit margin of SGRL?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.